Immunologic adjuvant

From Wikipedia, the free encyclopedia

In immunology, an adjuvant is an agent that may stimulate the immune system and increase the
response to a vaccine, without having any specific antigenic effect in itself.[1] The word
“adjuvant” comes from the Latin word adiuvare, meaning to help or aid.[2] "An immunologic
adjuvant is defined as any substance that acts to accelerate, prolong, or enhance antigen-specific
immune responses when used in combination with specific vaccine antigens."[3]

Adjuvants have been whimsically called the dirty little secret of vaccines[4] in the scientific
community. This dates from the early days of commercial vaccine manufacture, when significant
variations in the effectiveness of different batches of the same vaccine were observed, correctly
assumed to be due to contamination of the reaction vessels. However, it was soon found that
more scrupulous attention to cleanliness actually seemed to reduce the effectiveness of the
vaccines, and that the contaminants – "dirt" – actually enhanced the immune response. There are
many known adjuvants in widespread use, including oils, aluminium salts, and virosomes,
although precisely how they work is still not entirely understood.

Contents
[hide]

 1 Overview
o 1.1 Inorganic adjuvants
 1.1.1 Aluminium salts
o 1.2 Organic adjuvants
 1.2.1 Oil-based
o 1.3 Virosomes
o 1.4 Experimental adjuvants
 2 Adjuvants and the adaptive immune response
 3 Adjuvants and toll-like receptors
 4 Medical complications
o 4.1 Humans
o 4.2 Animals
 5 Controversy
 6 See also
 7 External links
 8 References

[edit] Overview
Adjuvants in immunology are often used to modify or augment the effects of a vaccine by
stimulating the immune system to respond to the vaccine more vigorously, and thus providing
increased immunity to a particular disease. Adjuvants accomplish this task by mimicking
specific sets of evolutionarily conserved molecules, so called PAMPs, which include liposomes,
lipopolysaccharide (LPS), molecular cages for antigen, components of bacterial cell walls, and
endocytosed nucleic acids such as double-stranded RNA (dsRNA), single-stranded DNA
(ssDNA), and unmethylated CpG dinucleotide-containing DNA.[5] Because immune systems
have evolved to recognize these specific antigenic moieties, the presence of an adjuvant in
conjunction with the vaccine can greatly increase the innate immune response to the antigen by
augmenting the activities of dendritic cells (DCs), lymphocytes, and macrophages by mimicking
a natural infection.[6] Furthermore, because adjuvants are attenuated beyond any function of
virulence, they pose little or no independent threat to a host organism.[citation needed]

[edit] Inorganic adjuvants

[edit] Aluminium salts

There are many adjuvants, some of which are inorganic (such as alum), that also carry the
potential to augment immunogenicity.[7][8] Two common salts include aluminium phosphate and
aluminium hydroxide. These are the most common adjuvants in human vaccines.

[edit] Organic adjuvants

While Aluminium salts are popularly used in human vaccines, the organic compound Squalene is
also used. However, organic adjuvants are more commonly used in animal vaccines.

[edit] Oil-based

Oil-based adjuvants are commonly used in some veterinary vaccines.

[edit] Virosomes

Another market-approved adjuvant and carrier system are virosomes.[9] During the last two
decades, a variety of technologies have been investigated to improve the widely-used adjuvants
based on aluminium salts.[10] These salts are unfavorable, since they develop their effect by
inducing local inflammation, which is also the basis for the extended side-effect pattern of this
adjuvant. In contrast, the adjuvant capabilities of virosomes are independent of any inflammatory
reaction. Virosomes contain a membrane-bound hemagglutinin and neuraminidase derived from
the influenza virus, and serve to amplify fusogenic activity and therefore facilitate the uptake
into antigen presenting cells (APC) and induce a natural antigen-processing pathway. The
delivery of the antigen by virosomes to the immune system in a way that mimics a natural path
may be a reason why virosome-based vaccines stand out due to their excellent safety profile.[11]

[edit] Experimental adjuvants

An increasing number of vaccines with squalene and phosphate adjuvants are being tested on
humans.[12] The compound QS21 is under investigation as a possible immunological adjuvant[13]
as is Novartis' (formerly Chiron) MF59.[14]

[edit] Adjuvants and the adaptive immune response

One misconception concerning adjuvant function is that an adjuvant-enhanced innate immune
response should affect only the transient reaction of the innate immune response and not the
more long-lived effects of the adaptive immune response.[citation needed] Although it may appear
fitting to separate the two systems, it is however important to realize the interconnected nature of
the two systems. When the amount of communication that takes place between the innate
immune response and the adaptive immune response with the onset of infection is considered it
becomes difficult to separate the two systems.

In order to understand the links between the innate immune response and the adaptive immune
response to help substantiate an adjuvant function in enhancing adaptive immune responses to
the specific antigen of a vaccine, the following points should be considered:

 Innate immune response cells such as Dendritic Cells (DCs) engulf pathogens through a
process called phagocytosis.
 DCs then migrate to the lymph nodes where T cells (adaptive immune cells) wait for
signals to trigger their activation.[15]
 In the lymph nodes, DCs mince the engulfed pathogen and then express the pathogen
clippings as antigen on their cell surface by coupling them to a special receptor known as
a major histocompatibility complex (MHC).
 T cells can then recognize these clippings and undergo a cellular transformation resulting
in their own activation.[16]
 γδ T cells possess characteristics of both the innate and adaptive immune responses.
 Macrophages can also activate T cells in a similar approach (but do not do so naturally).

This process carried out by both DCs and macrophages is termed antigen presentation and
represents a physical link between the innate and adaptive immune responses.

Upon activation, mast cells release heparin and histamine to effectively increase trafficking to
and seal off the site of infection to allow immune cells of both systems to clear the area of
pathogens. In addition, mast cells also release chemokines which result in the positive
chemotaxis of other immune cells of both the innate and adaptive immune responses to the
infected area.[17][18]

Due to the variety of mechanisms and links between the innate and adaptive immune response,
an adjuvant-enhanced innate immune response results in an enhanced adaptive immune response.
Specifically, a recent study has observed that adjuvants may exert their immune-enhancing
effects according to five immune-functional activities.[19]
  First, it was found that adjuvants all help in the translocation of antigens to the lymph
nodes where they can be recognized by T cells. This will ultimately lead to greater T cell
activity resulting in a heightened clearance of pathogen throughout the organism.
 Second, adjuvants provide physical protection to antigens which grants the antigen a
prolonged delivery. This means that the organism will be exposed to the antigen for a
longer duration, making the immune system more robust as it makes use of the additional
time by upregulating the production of B and T cells needed for greater immunological
memory in the adaptive immune response.
 Third, adjuvants help to increase the capacity to cause local reactions at the injection site
(during vaccination), inducing greater release of danger signals by chemokine releasing
cells such as helper T cells and mast cells.
 Fourth, they induce the release of inflammatory cytokines which helps to not only recruit
B and T cells at sites of infection but also to increase transcriptional events leading to a
net increase of immune cells as a whole.
 Finally, adjuvants are believed to increase the innate immune response to antigen by
interacting with pattern recognition receptors (PRRs), specifically Toll-like receptors
(TLRs), on accessory cells.

[edit] Adjuvants and toll-like receptors

The ability of immune system to recognize molecules that are broadly shared by pathogens is, in
part, due to the presence of special Immune receptors called TLRs that are expressed on
leukocyte membranes. TLRs were first discovered in drosophila, and are membrane bound
pattern recognition receptors (PRRs) responsible for detecting most (although certainly not all)
antigen-mediated infections.[20][21] In fact, some studies have shown that in the absence of TLR,
leukocytes become unresponsive (no inflammatory responses) to some microbial components
such as LPS.[22] There are at least thirteen different forms of TLR, each with its own
characteristic ligand. Prevailing TLR ligands described to date (all of which elicit adjuvant
effects) include many evolutionarily conserved molecules such as LPS, lipoproteins,
lipopeptides, flagellin, double-stranded RNA, unmethylated CpG islands and various other forms
of DNA and RNA classically released by bacteria and viruses.[23][24][25][26][27][28]

The binding of ligand - either in the form of adjuvant used in vaccinations or in the form of
invasive moieties during times of natural infection - to the TLR marks the key molecular events
that ultimately lead to innate immune responses and the development of antigen-specific
acquired immunity.[29][30] The very fact that TLR activation leads to adaptive immune responses
to foreign entities explains why so many adjuvants used today in vaccinations are developed to
mimic TLR ligands.

It is believed that upon activation, TLRs recruit adapter proteins (proteins that mediate other
protein-protein interactions) within the cytosol of the immune cell in order to propagation the
antigen-induced signal transduction pathway. To date, four adapter proteins have been well-
characterized. These proteins are known as MyD88, Trif, Tram and Tirap (also called Mal).[31][32]
[33][34]
These recruited proteins are then responsible for the subsequent activation of other
downstream proteins, including protein kinases (IKKi, IRAK1, IRAK4, and TBK1) that further
amplify the signal and ultimately lead to the upregulation or suppression of genes that orchestrate
inflammatory responses and other transcriptional events. Some of these events lead to cytokine
production, proliferation, and survival, while others lead to greater adaptive immunity.[30] The
high sensitivity of TLR for microbial ligands is what makes adjuvants that mimic TLR ligands
such a prime candidate for enhancing the overall effects of antigen specific vaccinations on
immunological memory.

Finally, the expression of TLRs is vast as they are found on the cell membranes of innate
immune cells (DCs, macrophages, natural killer cells), cells of the adaptive immunity (T and B
lymphocytes) and non immune cells (epithelial and endothelial cells, fibroblasts).[35]

This further substantiates the importance of administering vaccines with adjuvants in the form of
TLR ligands as they will be capable of eliciting their positive effects across the entire spectrum
of innate and adaptive immunity. Nevertheless, there are certainly adjuvants whose immune-
stimulatory function completely bypasses the putative requisite for TLR signaling. In short, all
TLR ligands are adjuvants but not all adjuvants are TLR ligands.

[edit] Medical complications

[edit] Humans

Aluminium salts used in many human vaccines are generally regarded as safe.[36]

[edit] Animals

Aluminum adjuvants have caused motor neuron death in mice[37] and oil-water suspensions have
been reported to increase the risk of autoimmune disease in mice.[38] Squalene has caused
rheumatoid arthritis in rats already prone to arthritis.[39]

In cats, vaccinations have been linked to sarcomas,